As of the date of this report, patients with idiopathic anaphylaxis continue to be admitted for study. The majority of the patients are admitted to the inpatient unit and undergo a bone marrow procedure in an attempt to elucidate the etiology and evaluate the pathogenesis of their disease. Patients also have research blood drawn along with routine labs. In collaboration with the NIH Clinical Center's myeloid core facility, we assess all the patient bone marrow aspirates and biopsies obtained based on the current WHO criteria to diagnose systemic mastocytosis. Mast cells derived from peripheral mononuclear cells are being cultured and examined for mast cell growth and activation studies in comparison to mast cells from healthy volunteers. In one facet of the study and in exploring differences in human mast cell responses related to donor, we examined mast cell activation as influenced by PGE2 and selective PGE2-receptor ligands. We observed that human mast cells from approximately half of the donors failed to respond to PGE2 and the PGE2 EP3 receptor agonist, sulprostone. However, mast cells from the remaining donors and the LAD2 human mast cell line responded to PGE2 and sulprostone with marked enhancement of antigen-mediated degranulation and IL-8 production. The EP2 agonist, butaprost, failed to modulate antigen-mediated responses in any type of mast cell. These distinct phenotypes could not be explained by differences in EP2 or EP3 expression or by differences in the ability of PGE2 to elevate levels of cAMP. Moreover, both responder and non-responder mast cell populations exhibited similar activation of phosphatidylinositol 3-kinase, and MAP kinases. However, translocation of PLCgamma1 to the cell membrane and the associated calcium signal were enhanced only in the responder population. These data provide one reason for variability in human mast cell-dependent responses related to donor, as well as providing a basis for examining the effects of co-activating receptors in patients susceptible to allergic conditions. The randomized treatment protocol with omalizumab (09-I-0129) is in the patient accrual stage.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2012
Total Cost
$429,909
Indirect Cost
City
State
Country
Zip Code
Carter, M C; Ruiz-Esteves, K N; Workman, L et al. (2018) Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis. Allergy 73:1131-1134
Carter, Melody C; Desai, Avanti; Komarow, Hirsh D et al. (2018) A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. J Allergy Clin Immunol 141:180-188.e3
Metcalfe, Dean D; Mekori, Yoseph A (2017) Pathogenesis and Pathology of Mastocytosis. Annu Rev Pathol 12:487-514
Muñoz-Cano, Rosa; Pascal, Mariona; Bartra, Joan et al. (2016) Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis. J Allergy Clin Immunol 137:137-146
Boyden, Steven E; Metcalfe, Dean D; Komarow, Hirsh D (2016) Vibratory Urticaria and ADGRE2. N Engl J Med 375:95
Kotarek, Joseph; Stuart, Christine; De Paoli, Silvia H et al. (2016) Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events. J Pharm Sci 105:1023-7
Lyons, Jonathan J; Yu, Xiaomin; Hughes, Jason D et al. (2016) Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 48:1564-1569
Kirshenbaum, Arnold S; Cruse, Glenn; Desai, Avanti et al. (2016) Immunophenotypic and Ultrastructural Analysis of Mast Cells in Hermansky-Pudlak Syndrome Type-1: A Possible Connection to Pulmonary Fibrosis. PLoS One 11:e0159177
Metcalfe, Dean D; Pawankar, Ruby; Ackerman, Steven J et al. (2016) Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 9:7
Hox, Valerie; O'Connell, Michael P; Lyons, Jonathan J et al. (2016) Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis. J Allergy Clin Immunol 138:187-99

Showing the most recent 10 out of 23 publications